These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33476088)

  • 1. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
    Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
    IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
    Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
    Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
    Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
    Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
    Freudlsperger C; Burnett JR; Friedman JA; Kannabiran VR; Chen Z; Van Waes C
    Expert Opin Ther Targets; 2011 Jan; 15(1):63-74. PubMed ID: 21110697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
    Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.
    Xu R; Xu R; Wang Y; Wang W; Jiang L; Gong S
    Comput Math Methods Med; 2022; 2022():6881932. PubMed ID: 35116073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDK1 Mediates
    Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
    Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
    Psyrri A; Seiwert TY; Jimeno A
    Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
    Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
    Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma.
    Georgy SR; Cangkrama M; Srivastava S; Partridge D; Auden A; Dworkin S; McLean CA; Jane SM; Darido C
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26063791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.